Indivior : to Participate in Upcoming Healthcare Events During National Recovery Month
September 14, 2021 at 01:12 pm EDT
Share
Indivior to Participate in Upcoming Healthcare Events During National Recovery Month
Richmond, VA, September 14, 2021 - Indivior PLC, (LON: INDV) Indivior PLC, (LON: INDV) today announced that the Company's leadership will participate in two upcoming virtual events as part of our ongoing effort to raise awareness about the opioid crisis and to address barriers to evidence-based treatment, including unequal access to addiction treatment and supportin the U.S.
Financial Times: The Future of American HealthcareTuesday, September 14that 1:55 p.m. - 2:35 p.m. EDT
Indivior CEO Mark Crossley will participate in a panel discussion entitled "Mental health in a nation transformed by crisis" and share remarks about the impact of COVID-19 on opioid use disorder and how innovative policy and treatment options can better address the opioid epidemic. Registration to attend the event is available here.
The Hill: Advancing Health Equity in Our Nation's Opioid ResponseTuesday, September 21stat 1:00 p.m. EDT
Indivior Chief Scientific Officer Christian Heidbreder will share remarks during a panel discussion about disparities in addiction treatment among vulnerable populations. Registration to attend the event is available here.
September is National Recovery Month, a national observance to draw special attention to people struggling with substance use disorders and mental illnesses.
About Indivior
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and cooccurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 700 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
Indivior plc published this content on 14 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 September 2021 17:11:05 UTC.
Indivior PLC is a pharmaceutical company. The Company develops medicines to treat addiction and serious mental illnesses. The Company focuses on building a portfolio of opioid dependence treatments. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Its product pipeline focuses on development and discovery of non-opioid treatment strategies for opioid use disorder (OUD), as well as therapies to address the needs of people suffering from alcohol, stimulant, and cannabis use disorders. Its Sublocade, Subutex, and Suboxone are used for the treatment of opioid use disorder (OUD). Perseris is used for the treatment of Schizophrenia. The Company's pipeline products include AEF0117, INDV-2000, INDV-1000, RBP-6000, RBP-7000, Buprenorphine Sublingual and Naloxone Film, and Buprenorphine and Naloxone Sublingual Tablet. Its pipeline also includes the Orexin-1 Receptor Antagonist Program.
INDIVIOR PLC 
